Veradigm Health joins Harvard Pilgrim to develop next phase of FDA’s Sentinel System
October 10 2019 - 8:01AM
Business Wire
Five-year award signals FDA’s commitment to national program
utilizing electronic healthcare data to monitor the safety of
FDA-regulated drugs and other medical products
Veradigm™, an Allscripts (NASDAQ: MDRX) business unit dedicated
to simplifying healthcare with data-driven health insights and
technologies to help manage cost and improve health outcomes,
announced today that its Life Sciences business unit joins the
Harvard Pilgrim Healthcare Institute and other collaborating
partners to continue to develop the FDA Sentinel System, the
largest multisite distributed database in the world dedicated to
drug safety. The award focuses on two areas: first, managing the
Sentinel Operations Center, which builds upon the Institute’s 10
years of experience developing and operating the Sentinel System;
and second, developing a new Sentinel Innovation Center.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191010005125/en/
According to the FDA, the Operations Center will continue to
leverage organizational partnerships in the areas of epidemiology,
clinical medicine, pharmacy, statistics, health informatics, data
science and network operations, to support post approval safety
analyses. The Innovation Center will be focused on developing
innovative methods to further advance Sentinel, including exploring
novel ways to extract and structure information from electronic
health records (EHRs).
As a business unit of Allscripts, one of the world’s largest EHR
providers, Veradigm is especially well positioned to help the
Harvard Pilgrim team achieve FDA’s objective to better utilize
information from EHRs in the next phase of Sentinel development.
Veradigm currently offers HealthInsights, the largest deidentified
EHR database available for life sciences research (~150m patients)
that has been linked to integrated claims for certain research
studies. In addition, Veradigm collaborates with healthcare
providers to implement point-of-care research programs, engaging
patients and prospectively collecting additional data using
Allscripts EHR platforms.
“Veradigm is excited to collaborate with Harvard Pilgrim to
continue to advance the Sentinel System,” said Tom Langan, Chief
Executive Officer for Veradigm. “I believe our position as the Life
Sciences-focused business unit of Allscripts enables us to approach
the challenge in innovative ways, helping to increase efficiency,
responsiveness and the scale of Sentinel.”
About Veradigm™
Veradigm is an integrated data systems and services business
that combines data-driven clinical insights with actionable tools
for clinical workflow, research, analytics, and media. Our
solutions are designed to help key healthcare stakeholders to
improve the quality, efficiency, and value of healthcare delivery -
from biopharma to health plans, healthcare providers, health
technology partners, and most importantly, the patients they serve.
We are dedicated to simplifying the complicated healthcare system
with next-generation healthcare solutions. That is how we are
transforming health, insightfully. To learn more, visit
www.veradigmhealth.com. Veradigm™ is a business unit of
Allscripts.
About Allscripts
Allscripts (NASDAQ: MDRX) is a leader in healthcare information
technology solutions that advance clinical, financial and
operational results. Our innovative solutions connect people,
places and data across an Open, Connected Community of Health™.
Connectivity empowers caregivers to make better decisions and
deliver better care for healthier populations. To learn more, visit
www.allscripts.com, Twitter, YouTube and It
Takes A Community: The Allscripts Blog.
© 2019 Allscripts Healthcare, LLC and/or its affiliates. All
Rights Reserved.
Allscripts, the Allscripts logo, and other Allscripts marks are
trademarks of Allscripts Healthcare, LLC and/or its affiliates. All
other products are trademarks of their respective holders, all
rights reserved. Reference to these products is not intended to
imply affiliation with or sponsorship of Allscripts Healthcare, LLC
and/or its affiliates.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191010005125/en/
Investors: Stephen Shulstein
312-386-6735 Stephen.Shulstein@allscripts.com Media: Tom Lynch 312-386-6765
Tom.Lynch@allscripts.com
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From Apr 2024 to May 2024
Veradigm (NASDAQ:MDRX)
Historical Stock Chart
From May 2023 to May 2024